8-K: Harvard Bioscience Secures Fifth Amendment to Credit Agreement, Waives Covenant Breach

Harvard Bioscience obtains a waiver for a covenant breach and adjusts its credit facility terms to address refinancing milestones and liquidity concerns.

Summary

• Harvard Bioscience entered into a Fifth Amendment to its Credit Agreement on March 10, 2025.
• The amendment waives the company's non-compliance with the consolidated net leverage ratio covenant as of December 31, 2024.
• The lenders' commitment under the revolving credit facility is capped at the outstanding amount as of the amendment date.
• The amendment establishes milestones for refinancing the debt, including retaining an investment banker, engaging a financial advisor by March 14, 2025, and closing the refinancing by June 30, 2025.
• Financial covenants for the quarter ending March 31, 2025, will not be tested, provided the company meets payment obligations, refinancing milestones, maintains minimum liquidity of $3.5 million, and provides financial reports.
• The applicable interest rate margin is increased to SOFR plus 400 bps, and amortization payments are revised to monthly installments.
• The company paid $0.1 million in fees to the lenders in connection with the amendment.
• Harvard Bioscience is exploring alternative capital sources to refinance its debt by June 30, 2025, but access to such capital is uncertain.
• The company expects its cash and operations to finance operations and capital expenditures while refinancing.
• There is substantial doubt about the company's ability to continue as a going concern if it cannot refinance or extend its debt repayment by June 30, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the covenant breach, increased interest rates, and concerns about the company's ability to continue as a going concern. While the amendment provides some short-term relief, the long-term outlook is uncertain.

Positives

• The Fifth Amendment provides a waiver for non-compliance with the consolidated net leverage ratio covenant.
• The lenders have agreed not to test financial covenants for the fiscal quarter ended March 31, 2025, under certain conditions.
• The company is actively exploring alternative sources of capital for refinancing.
• The company expects available cash and cash generated from operations will be sufficient to finance operations and capital expenditures while working to refinance the Credit Agreement.

Negatives

• The lenders' commitment under the revolving credit facility is capped.
• The applicable interest rate margin is increased to SOFR plus 400 bps.
• There is substantial doubt about the company's ability to continue as a going concern if it cannot refinance or extend its debt repayment by June 30, 2025.

Risks

• The company's ability to access other sources of capital adequate to refinance the indebtedness by June 30, 2025, is uncertain.
• Failure to refinance the indebtedness by June 30, 2025, or extend such date for repayment, will result in the company being unable to pay its debt obligations and fund its operations beyond that date.
• The company's ability to continue as a going concern is in substantial doubt.

Future Outlook

The company is exploring alternative sources of capital to refinance its outstanding indebtedness by June 30, 2025. However, the company's ability to access such other sources of capital is uncertain. Unless the company is able to access other sources of capital adequate to refinance the indebtedness by June 30, 2025, or extend such date for repayment, it will be unable to pay its debt obligations and fund its operations beyond that date.

Industry Context

This announcement reflects a company facing financial challenges and working to restructure its debt. Similar situations are common in the current economic environment, where companies are navigating increased interest rates and tighter credit conditions. Other companies in the bioscience sector may be facing similar pressures.

Comparison to Industry Standards

• It is difficult to compare Harvard Bioscience's situation to industry standards without specific details on its financial performance relative to its peers.
• However, covenant breaches and restructuring efforts are not uncommon in the bioscience industry, particularly for smaller companies with limited revenue streams.
• Comparable companies undergoing similar financial restructurings may include those with high debt loads and challenges in achieving profitability.
• The success of the refinancing efforts will be a key indicator of the company's long-term viability.

Stakeholder Impact

• Shareholders face uncertainty due to the company's financial challenges and potential inability to continue as a going concern.
• Employees may be concerned about job security if the company cannot refinance its debt.
• Customers and suppliers may be wary of doing business with a company facing financial difficulties.
• Creditors face increased risk of non-payment if the company cannot refinance its debt.

Next Steps

• The company must continue to retain an investment banker.
• The company must engage a financial advisor acceptable to the administrative agent by March 14, 2025.
• The company must deliver an executed bona fide indication of interest from one or more potential lenders with respect to the Refinancing by April 30, 2025.
• The company must deliver a term sheet or commitment letter from one or more potential lenders that provides for the Refinancing by May 23, 2025.
• The company must deliver a statement of sources and uses of transaction proceeds and evidence that the potential lenders' conditions to closing are satisfied by June 13, 2025.
• The company must close the Refinancing by June 30, 2025.

Key Dates

Keywords

refinancing, credit agreement, debt, harvard bioscience, covenant, liquidity, amendment, financing